Meningioma: Systemic Therapy Perspective

  • Steven Grunberg


Meningiomas pose a dilemma for the oncologist. Although meningiomas are indeed tumors (i.e., abnormal tissue growth), most meningiomas are histologically benign. The morbidity of this condition is generally not related to rapid invasive growth or to metastases, the properties that define malignancies. Instead, symptoms of this condition are primarily due to location. Slow tumor growth in the extremities or trunk can remain asymptomatic and undetected for extended periods of time. Retroperitoneal tumors, such as nonfunctioning adrenocortical carcinoma, can easily reach 10 cm in size before clinical symptoms are apparent [1]. However, there is only a fixed amount of space within the skull. If one structure increases in size, another must give way, usually with the appearance of neurologic symptoms. The proximity of vital neurologic structures can also rapidly lead to complex neurologic deficits while making the physical approach to the tumor mass more difficult. Because meningioma tends to be a localized problem, the use of localized modalities is the logical therapeutic approach, and the use of systemic modalities, which may also result in systemic toxicities, must be adequately justified.


Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Inhibitor Adrenocortical Carcinoma Meningioma Cell Malignant Meningioma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Macfarlane DA. Cancer of the adrenal cortex. Ann Roy Coll Surg Engl 1958; 23:155–186.Google Scholar
  2. 2.
    Qureshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet 2004; 363:804–813.CrossRefPubMedGoogle Scholar
  3. 3.
    Grunberg SM, Burris H 3rd, Livingston R. The price of success. J Clin Oncol 1995; 13:797–798.PubMedGoogle Scholar
  4. 4.
    Kleinberg L, Wallner K, Malkin MG. Good performance status of long-term disease-free survivors of intracranial gliomas. Int J Radiat Oncol Biol Phys 1993; 26:129–133.PubMedGoogle Scholar
  5. 5.
    Surma-aho O, Niemelä M, Vilkki J, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001; 56:1285–1290.PubMedGoogle Scholar
  6. 6.
    Gregor A, Cull A, Traynor E, et al. Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol 1996; 41:55–59.PubMedGoogle Scholar
  7. 7.
    Brown PD, Buckner JC, O’Fallon JR, et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein Mini-Mental State Examination. J Clin Oncol 2003; 21:2519–2524.CrossRefPubMedGoogle Scholar
  8. 8.
    Kyritsis AP. Chemotherapy for meningiomas. J Neurooncol 1996; 29:269–272.CrossRefPubMedGoogle Scholar
  9. 9.
    Travitzky M, Libson E, Nemirovsky I, et al. Doxil-induced regression of pleuro-pulmonary metastases in a patient with malignant meningioma. Anticancer Drugs 2003; 14:247–250.CrossRefPubMedGoogle Scholar
  10. 10.
    Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology 2004; 62:1210–1212.PubMedGoogle Scholar
  11. 11.
    Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 1997; 86:840–844.CrossRefPubMedGoogle Scholar
  12. 12.
    Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 1997; 86:845–852.CrossRefPubMedGoogle Scholar
  13. 13.
    Mason WP, Gentili F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 2002; 97:341–346.CrossRefPubMedGoogle Scholar
  14. 14.
    Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 2004; 18:495–499.CrossRefPubMedGoogle Scholar
  15. 15.
    Paus S, Klockgether T, Schlegel U, et al. Meningioma of the optic nerve sheath: treatment with hydroxyurea. J Neurol Neurosurg Psychiatry 2003; 74:1348–1350.CrossRefPubMedGoogle Scholar
  16. 16.
    Loven D, Hardoff R, Sever ZB, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 2004; 67:221–226.CrossRefPubMedGoogle Scholar
  17. 17.
    Koper JW, Zwarthoff EC, Hagemeijer A, et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur J Cancer 1991; 27:416–419.CrossRefPubMedGoogle Scholar
  18. 18.
    Muhr C, Gudjonsson O, Lilja A, et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res 2001; 7:2269–2276.PubMedGoogle Scholar
  19. 19.
    Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997; 20:271–275.CrossRefGoogle Scholar
  20. 20.
    Boyle-Walsh E, Hashim IA, Speirs V, et al. Interleukin-6 (IL-6) production and cell growth of cultured human meningiomas: interactions with interleukin-1 beta (IL-1 beta) and interleukin-4 (IL-4) in vitro. Neurosci Lett 1994; 170:129–132.CrossRefPubMedGoogle Scholar
  21. 21.
    Lin CC, Kenyon L, Hyslop T, et al. Cyclooxygenase-2 (COX-2) expression in human meningioma as a function of tumor grade. Am J Clin Oncol 2003; 26:S98–102.CrossRefPubMedGoogle Scholar
  22. 22.
    Nathoo N, Barnett GH, Golubic M. The eicosanoid cascade: possible role in gliomas and meningiomas. J Clin Pathol 2004; 57:6–13.CrossRefPubMedGoogle Scholar
  23. 23.
    Pistolesi S, Fontanini G, Boldrini L, et al. The role of somatostatin in vasogenic meningioma associated brain edema. Tumori 2003; 89:136–140.PubMedGoogle Scholar
  24. 24.
    Quest DO. Meningiomas: an update. Neurosurgery 1978; 3:219–225.CrossRefPubMedGoogle Scholar
  25. 25.
    Schoenberg BS, Christine BW, Wisnant JP. Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 1974; 25:705–712.Google Scholar
  26. 26.
    Cushing H, Eisenhardt L. Meningiomas arising from the tuberculum sellae with the syndrome of primary optic atrophy and bitemporal field defects combined with a normal sella turcica in a middle-aged person. Arch Ophthalmol 1929; 1:1–41.Google Scholar
  27. 27.
    Grunberg SM. The role of progesterone receptors in meningioma. In: Muggia FM, ed. New drugs, concepts and results in cancer chemotherapy. Boston: Kluwer Academic Publishers, 1992:127–137.Google Scholar
  28. 28.
    Olsson JJ, Beck DW, Schlechte J, et al. Hormonal manipulation of meningiomas in vitro. J Neurosurg 1986; 65:99–107.CrossRefGoogle Scholar
  29. 29.
    Olsson JJ, Beck DW, Schlechte JA, et al. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J Neurosurg 1987; 66:584–587.CrossRefGoogle Scholar
  30. 30.
    Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006; 24:727–733.CrossRefPubMedGoogle Scholar
  31. 31.
    Grunberg SM, Rankin C, Townsend J, et al. Phase III double-blind randomized placebo-controlled study of mifepristone for the treatment of unresectable meningioma. Proc Am Soc Clin Oncol 2001; 20:56A.Google Scholar
  32. 32.
    Kuratsu JI, Seto H, Kochi M, et al. Expression of PDGF, PDGF-receptor, EGF-receptor and sex hormone receptors on meningioma. Acta Neurochir (Wien) 1994; 131:289–293.CrossRefGoogle Scholar
  33. 33.
    Andersson U, Guo D, Malmer B, et al. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol (Berl) 2004; 108:135–142.CrossRefGoogle Scholar
  34. 34.
    Torp SH, Helseth E, Dalen A, et al. Expression of epidermal growth factor receptor in human meningiomas and meningeal tissue. APMIS 1992; 100:797–802.CrossRefPubMedGoogle Scholar
  35. 35.
    Carroll RS, Black PM, Zhang J, et al. Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 1997; 87:315–323.CrossRefPubMedGoogle Scholar
  36. 36.
    Sanfilippo JS, Rao CV, Guarnaschelli JJ, et al. Detection of epidermal growth factor and transforming growth factor alpha protein in meningiomas and other tumors of the central nervous system in human beings. Surg Gynecol Obstet 1993; 177:488–496.PubMedGoogle Scholar
  37. 37.
    Camby I, Nagy N, Rombaut K, et al. Influence of epidermal growth factor and gastrin on the cell proliferation of human meningiomas versus astrocytic tumors maintained as ex vivo tissue cultures. Neuropeptides 1997; 31:217–225.CrossRefPubMedGoogle Scholar
  38. 38.
    Dirven CM, Grill J, Lamfers ML, et al. Gene therapy for meningioma: improved gene delivery with targeted adenoviruses. J Neurosurg 2002; 97:441–449.CrossRefPubMedGoogle Scholar
  39. 39.
    Koper JW, Lamberts SWJ. Meningiomas, epidermal growth factor and progesterone. Human Reprod 1994; 1(9 Suppl):190–193.Google Scholar
  40. 40.
    Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006; 24:727–733.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Steven Grunberg
    • 1
  1. 1.Department of Medical OncologyBurlingtonUSA

Personalised recommendations